Therapeutic regimens for treatment of paroxysmal nocturnal hemoglobinuria

Inactive Publication Date: 2019-02-07
ACHILLION PHARMA INC
View PDF4 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0008]Provided herein are methods for treating a subject with PNH comprising administering to a subject a therapeutically effective amount of complement component C5 (C5) inhibitor, complement component C3 (C3) inhibitor, or complement factor B (CFB) inhibitor in combination with a therapeutically effective amount of small molecule complement factor D (CFD) inhibitor. By including a CFD inhibitor described herein in combination with, or following administration of, a C5 inhibitor, C3 inhibitor, or a CFB inhibitor, significant improvement in the inhibition of intravascular hemolysis associated with PNH is atta

Problems solved by technology

While eculizumab binds to C5 and blocks the terminal pathway of complement upstream of CD59, it does not address the deposition of C3 fragments as a result of the complement alte

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Therapeutic regimens for treatment of paroxysmal nocturnal hemoglobinuria
  • Therapeutic regimens for treatment of paroxysmal nocturnal hemoglobinuria
  • Therapeutic regimens for treatment of paroxysmal nocturnal hemoglobinuria

Examples

Experimental program
Comparison scheme
Effect test

Example

Example 1. Inhibitory Activity of Compound 1 in Combination with Eculizumab as Assessed Via a CAP-Mediated Hemolysis Assay with PNH Erythrocytes

[0214]The inhibitory activity of Compound 1 and the humanized monoclonal antibody Eculizumab was assessed via a CAP-mediated hemolysis assay with PNH erythrocytes from subjects (described in Example 3). The CAP-mediated hemolysis assay with PNH erythrocytes was conducted two independent times and then analyzed by the method of Prichard and Shipman (described in Example 4). The inhibition of CAP activity for each experiment is shown in Table 2. The analytical results for each experiment, along with summary information, are shown in Table 3. The three-dimensional surface-graphs used in the analysis method of Prichard and Shipman are shown in FIGS. 1A-1B.

TABLE 2Inhibition of CAP activity of Compound 1 and EculizumabEculiz-Compound 1 (μM)umaba00.02340.04690.09380.1880.3750.751.5Inhibition (%), Experiment #1400343735365676919720025312931557088981...

Example

Example 2. Inhibitory Activity of Compound 1 in Combination with Compstatin as Assessed Via a CAP-Mediated Hemolysis Assay with PNH Erythrocytes

[0216]The inhibitory activity of Compound 1 and the complement C3 inhibitor Compstatin was assessed via a CAP-mediated hemolysis assay with PNH erythrocytes from subjects (described in Example 3). The CAP-mediated hemolysis assay with PNH erythrocytes was conducted two independent times and then analyzed by the method of Prichard and Shipman (described in Example 4) and by the method of Chou and Talalay (described in Example 5). The inhibition of CAP activity for each experiment is shown in Table 4. The analytical results for each experiment are shown in Table 5. The three-dimensional surface-graphs used in the analysis method of Prichard and Shipman are shown in FIGS. 2A-2B.

TABLE 4Inhibition of CAP activity of Compound 1 and Compstatin measured using the CAP-mediated hemolysis assay with PNH ErythrocytesComp-statin(μM)Compound 1 (μM)Inhibit...

Example

Example 3. CAP-mediated Hemolysis Assay with Erythrocytes from PNH Subject A

[0219]Combination studies of Compound 1 with Eculizumab (results are described in Example 1) and Compound 1 with Compstatin (results are described in Example 2) were performed using the CAP-mediated hemolysis assay with erythrocytes from PNH subject A and blood group ABO-compatible serum (NHS-AB, final assay concentration 20%). PNH Subject hematologic characteristics are shown in Table 6.

TABLE 6Characteristics of Subject AAge, Gender52, FBlood typeBErythrocyte clone size Type II / III (%)3.1 / 88Granulocyte clone size (%)99LDH (U / L)293Hemoglobin (g / dL)9.8Direct Coombs C3PosDirect Coombs IgGNegAbsolute reticulocyte count (K / cu mm)288.3Start of Eculizumab useStarted March 2011

[0220]Compound 1 and Compstatin were prepared as 15 mM stocks in DMSO. Eculizumab was obtained as a 10 mg / mL stock in buffered saline. Complement-preserved normal human serum (NETS) from an individual donor of ABO blood group type AB (NHS-AB)...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Timeaaaaaaaaaa
Timeaaaaaaaaaa
Densityaaaaaaaaaa
Login to view more

Abstract

Provided herein are methods for treating a subject with PNH comprising administering to a subject a therapeutically effective amount of complement component C5 (C5) inhibitor, complement component C3 (C3) inhibitor, or complement factor B (CFB) inhibitor in combination with a therapeutically effective amount of small molecule complement factor D (CFD) inhibitor of Formula I or Formula II, or a pharmaceutically acceptable salt thereof.

Description

STATEMENT OF RELATED APPLICATIONS[0001]This application claims the benefit of U.S. Provisional Application No. 62 / 540,451, filed on Aug. 2, 2017, and U.S. Provisional Application No. 62 / 593,669, filed Dec. 1, 2017. The entirety of each of these applications is incorporated herein by reference for all purposes.FIELD OF THE INVENTION[0002]This invention is in the area of therapeutic regimens for the treatment of the complement-mediated disorder paroxysmal nocturnal hemoglobinuria (PNH).BACKGROUND OF THE INVENTION[0003]The complement system is a part of the innate immune system which does not adapt to changes over the course of the host's life, but is recruited and used by the adaptive immune system. For example, it assists, or complements, the ability of antibodies and phagocytic cells to clear pathogens. This sophisticated regulatory pathway allows rapid reaction to pathogenic organisms while protecting host cells from destruction. Over thirty proteins and protein fragments make up t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/506A61K39/395C07K16/18A61P7/00
CPCA61K31/506A61K39/3955C07K16/18A61P7/00A61K2039/505C07K2317/76A61K2300/00
Inventor HUANG, MINGJUNPATEL, DHARABENPODOS, STEVEN D.
Owner ACHILLION PHARMA INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap